Comparative Pharmacology
Head-to-head clinical analysis: REXULTI versus TOVALT ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REXULTI versus TOVALT ODT.
REXULTI vs TOVALT ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A and α1B/α2C adrenergic receptors.
Tovalt ODT (selegiline) is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). At therapeutic doses, it inhibits MAO-B more selectively than MAO-A, leading to increased levels of dopamine in the brain.
2 mg orally once daily initially; increase to 4 mg once daily no sooner than week 2; target dose 4 mg once daily; range 2-4 mg once daily.
20 mg sublingually as needed for BTP, with a minimum interval of 2 hours between doses; maximum 4 doses per day.
None Documented
None Documented
Terminal elimination half-life is approximately 19–23 days for brexpiprazole and its major metabolite DM-3411, requiring up to 2–3 months to reach steady state.
Terminal elimination half-life approximately 40–60 hours after multiple dosing; clinical context: reaches steady-state after 2–3 weeks.
Approximately 25% of the dose is excreted in urine as unchanged drug and metabolites; about 54% is excreted in feces. Renal excretion of unchanged drug is minor (<1%).
Primarily hepatic metabolism; 70–80% as inactive metabolites in urine, <5% unchanged in urine, 20–30% fecal.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic